U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19, the disease caused by the CCP virus. “The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising,” said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies. California OKs Reopening of Ball Parks, Disneyland California has cleared a path for fans to hit the stands at opening-day baseball games and return to Disneyland nearly a year after CCP (Chinese Communist Party) virus restrictions shuttered major entertainment spots. New public health rules would allow live concerts at stadiums and sports arenas to reopen with limited attendance April 1. …
Read More
RSS Feed | The Epoch Times
